Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03199651 · ClinicalTrials.gov registry record · NA
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
A NA study of Stage IV Non-small Cell Lung Cancer and Lung Adenocarcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 3,584
- Enrollment target
- 1
- Study location
NCT03199651 is a NA study of Stage IV Non-small Cell Lung Cancer and Lung Adenocarcinoma that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 3,584 participants, above the 534-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (571% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03199651, a NA study of Stage IV Non-small Cell Lung Cancer and Lung Adenocarcinoma, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 3,584 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
- OTHER Medical Chart Review
- OTHER Best Practice
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,584 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03199651
The ClinicalTrials.gov registry entry for NCT03199651 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 3,584 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 534-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (571% higher). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT03199651 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03199651 about?
NCT03199651 is a clinical study titled "Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer". This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorabl...
What is the current status of trial NCT03199651?
This trial is currently recruiting. It is a NA study. The enrollment target is 3,584 participants. The study started on 2017-07-17. Estimated completion is 2028-12-31.
What conditions does trial NCT03199651 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Lung Adenocarcinoma, Cigarette Smoker, Current Smoker, Squamous Cell Lung Carcinoma.
What interventions are being tested in trial NCT03199651?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Medical Chart Review (OTHER), Best Practice (OTHER).
Who is sponsoring clinical trial NCT03199651?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03199651 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
COMPLETED · NA
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.